Skip to main
EPRX

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals, Inc. has demonstrated a compelling competitive advantage with its product EP-104 for eosinophilic esophagitis (EoE), showing higher per-patient efficacy compared to incumbent therapies like dupilumab, which typically yields histologic remission rates of 56-60%. The RESOLVE trial data displayed sustained symptom improvement and significant efficacy ceilings in high-dose cohorts, achieving up to 97% improvement in the EoE Health Symptom Severity (EoEHSS) scale and approximately 79% clinical remission following a single treatment. Furthermore, the removal of a potential competitor, validated by recent announcements, reinforces Eupraxia's strategic positioning in the market, highlighting the innovative and effective nature of the Diffusphere technology in addressing unmet medical needs.

Bears say

Eupraxia Pharmaceuticals Inc is facing a negative outlook largely due to several inherent risks, including clinical development, regulatory, and commercial risks associated with the introduction of EP-104 in a competitive market dominated by established players and cheaper off-label alternatives. Additionally, the company's reliance on continued R&D spending, coupled with uncertainties regarding financing to sustain operations beyond its current cash runway, contributes to concerns about its long-term viability. Furthermore, potential challenges such as cross-border supply issues and tariffs add another layer of risk that could further complicate Eupraxia's path to market success.

EPRX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Buy based on their latest research and market trends.

According to 2 analysts, EPRX has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.